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Alcohol activates chromatin in hepatic stellate 
cells (HSCs)
The impact of alcohol on HSCs is poorly understood. Elegant 
studies by Page et al. now reveal that HSCs respond to ethanol 
exposure by increasing the expression of genes coding for 
proteins of the extracellular matrix including elastin. They show 
that the lysine (K)-specific methyltransferase 2A (KMT2A, a 
histone-modifying enzyme also known as MLL1) is induced by 
ethanol and recruited to the elastin gene promoter where it is 
associated with enriched trimethylation of histone H3 at lysine 
4 (H3K4me3), which marks active (“relaxed”) chromatin. 
Moreover, they identified 41 gene loci at which both KMT2A and 
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R2 = 0.096LIVER FIBROSIS
Tregs inhibits anti-
fibrogenic NK 
cells, shear wave 
elastography to assess 
fibrosis
NK cells have anti-fibrogenic 
function by killing activated 
HSCs. Using elegant 
experiments involving regulatory 
CD4+ T cells (Tregs) from 
healthy subjects and patients 
with hepatitis C, Langhans et 
al. show that Tregs inhibit NK 
cell activity via both direct 
cell-contact mechanisms and 
release of soluble factors. 
Since there is intrahepatic 
accumulation of Tregs in chronic 
hepatitis C, this may result in 
NK cell down-regulation and 
subsequent unrestricted HSC 
“profibrogenic” activity.
The gold standard for the 
staging of liver fibrosis is liver 
biopsy. Several non-invasive 
diagnostic approaches have 
been developed during the last 
decade including 1D transient 
elastography (FibroScan). 
Deffieux et al. enrolled 
prospectively 120 patients with 
various chronic liver diseases 
to compare the accuracy 
of Supersonic Shearwave 
Imaging, a technique based on 
acoustic radiation and ultrafast 
ultrasound imaging to FibroScan 
for the staging and grading of 
fibrosis as assessed by liver 
biopsy. They also evaluated the 
ability of viscosity (a property 
of soft tissues) to predict 
fibrosis, steatosis and disease 
activity. The results show 
that Supersonic Shearwave 
Imaging is as accurate as 
FibroScan for the staging of 
fibrosis. This study also reveals 
that liver viscosity is correlated 
to fibrosis but not to steatosis or 
disease activity.
LIVER CANCER
Role of TRIM24, 
targeting β-catenin, 
hepatocellular 
carcinoma (HCC) in 
Caucasians receiving 
antiviral therapies for 
HBV
TRIM24 belongs to the tripartite 
motif containing (TRIM) family. It 
is a transcriptional co-activator 
that interacts with numerous 
nuclear receptors (including 
the estrogen, retinoic acid, and 
vitamin D3 receptors) and co-
activators, and modulates the 
transcription of target genes. 
The role of TRIM24 in liver 
cancer is unclear. To address 
this question Jiang et al. used 
two mouse models: the first 
one had global loss of Trim24 
transcript variants due to germ 
line deletion of the promoter 
and exon 1 in the Trim24 gene; 
the second model had a liver-
specific deletion of the gene. 
Deleted mice are not obese. 
In the absence of high fat 
diet, global or liver-specific 
deletion of Trim24 results in 
steatosis, liver fibrosis and 
development of HCC. This 
study unravels a mouse model 
that recapitulates the natural 
history of human NAFLD.
β-catenin (encoded by CTNNB1) 
is a key downstream component 
of the canonical Wnt signaling 
pathway. In the absence of 
Wnt, it forms a complex with 
AXIN1, AXIN2, APC, CSNK1A1 
and GSK3β that promotes 
ubiquitination of β-catenin 
and its degradation by the 
proteasome. In the presence 
of Wnt ligand, β-catenin is not 
ubiquitinated and accumulates 
in the nucleus, where it acts as 
a coactivator for transcription 
factors of the TCF/LEF family, 
leading to the activation of Wnt 
responsive genes. Mutations 
in CTNNB1 are common in 
patients with HCC resulting in 
β-catenin nuclear accumulation. 
The impact of in vivo β-catenin 
inhibition in “CTNNB1–mutated” 
HCC is unknown. Delgado 
et al. used a locked nucleic 
acid antisense suppressing 
β-catenin in a murine HCC 
model driven by CTNNB1 
mutations. They provide in vivo 
proof-of-concept that β-catenin 
suppression is associated with 
significant therapeutic effects 
in “CTNNB1–mutated” HCC.
The risk of HCC in Caucasian 
patients with chronic hepatitis 
B treated with entecavir or 
tenofovir is unclear. In a large, 
multicenter, retrospective cohort 
study that enrolled 1666 adults 
with chronic hepatitis B receiving 
antiviral therapy Papatheodoridis 
et al. now show that HCC can 
develop in these patients. 
More importantly, this study 
reveals that HCC risk scores 
developed in Asians have 
poor applicability in Caucasian 
patients, for whom different 
risk scores are required.
NON-ALCOHOLIC LIVER 
DISEASE (NAFLD)
PTEN, arginase 2, and 
cholesterol-derived 
molecules
Four studies provide new 
insights into mechanisms of 
non-alcoholic steatohepatitis 
(NASH), particularly those 
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and inflammation. Peryou et 
al. demonstrated that PTEN –a 
lipid/protein phosphatase– is 
downregulated in steatotic livers, 
thereby promoting a crosstalk 
between the liver and muscles 
and adipose tissue, resulting 
in enhanced insulin sensitivity 
in those organs. Navarro et 
al. focused on the role of 
innate immune system in fat 
accumulation and subsequent 
liver injury. They studied 
arginase 2, which competes with 
iNOS for its substrate, thereby 
regulating immune responses. 
The authors identified arginase 
2 as novel link between innate 
immune responses, hepatic 
lipid deposition, and liver injury. 
In another study, Hendrikx 
et al. investigated the role of 
Kupffer cells-derived cholesterol. 
They provided evidence 
that 27-hydroxycholesterol 
cholesterol derived from 
Kupffer cells reduces hepatic 
inflammation, further pointing 
towards these cells as specific 
target for improving therapy 
of NASH. Finally, an elegant 
human study from Bril et al. 
studied the link between vitamin 
D and NASH severity. Their 
study results strongly suggest 
that plasma vitamin D levels 
are not associated with insulin 
resistance, the amount of liver 
fat accumulation, or the severity 
of NASH. They clearly question 
the potential role of vitamin D 
supplementation in this disease.
VIRAL HEPATITIS
HCV and metabolic liver 
zonation, T-cells help 
B-cells, the future of 
HCV burden, real world 
data from TARGET and 
others, MATTERHORN 
Phase II study
Metabolic liver functions are 
carried out by distinct sets of 
hepatocytes, whose metabolic 
identity in a healthy liver is 
determined by their position 
within the lobule (metabolic 
zonation). The study by Moreau 
et al., using transgenic mice, 
provides evidence that even 
low levels of hepatitis C 
viral proteins can influence 
and alter hepatic metabolic 
zonation, targeting especially 
major lipogenic enzymes. 
These findings open new 
perspectives for the study of 
HCV-related pathology.
Whether T cells are able to 
give help to B cells, hereby 
stimulating humoral immune 
response against HCV 
infection, was studied by 
Spaan et al. They examined 
the frequency and phenotype 
of circulating and intrahepatic 
CD4+CXCR5+ T cells (the 
counterparts of germinal center 
T follicular helper (TFH)-cells) 
and their relation to B-cells. 
Their finding of intrahepatic 
TFH-cells in infiltrates and 
follicular structures opens 
new possibilities for studying 
B-T cell interactions and may 
be of relevance for a better 
understanding of the HCV-
associated immunopathology.
Aspinall et al. nicely 
demonstrated, in an international 
comparison, that the risk of 
liver-related mortality after 
a diagnosis of HCV has 
remained stable or increased. 
This provides further evidence 
that HCV treatment programs 
used so far had minimal 
impact on population level 
HCV-related liver disease. 
Scaling-up antiviral therapy is 
needed, and the Scottish study 
by McDonald et al. confirmed 
for the first time that SVR rates 
being maintained despite the 
broadening of the treated 
patient base. 
The large TARGET real 
world cohort by Gordon et al. 
including 2084 patients from 90 
centers shows a surprisingly 
low SVR rate of 52% in HCV 
type 1 infected patients and 
highlighted the high side 
effect profile of first generation 
protease inhibitor (PI) triple 
regimen. Quite in line with these 
observations are the results from 
a retrospective study presented 
by Londoño et al. showing that 
first generation PI triple therapy 
carries a high risk of infection 
in patients with cirrhosis and 
changes the pattern of infection 
towards respiratory tract 
infections. A quadruple regimen 
combining ritonavir-boosted 
danoprevir (danoprevir/r), 
mericitabine plus PegIFNα-2a 
and ribavirin produced a high 
overall SVR24 rates in prior 
partial and null responders. 
However, the IFN-free 
danoprevir/r plus mericitabine 
regime led to unacceptable 
high relapse rates as outlined 
in the phase II MATTERHORN 
study by Feld et al.
PORTAL 
HYPERTENSION
The two sides of portal 
hypertensive therapies
Strategies for the treatment of 
portal hypertension are limited. 
The study by Mookerjee et al. 
describes a novel target for the 
treatment of portal hypertension. 
In a rat model they show for 
the first time that gene therapy 
using a DDAH-1 plasmid 
corrected portal hypertension 
by normalizing endothelial 
NOS activity. On the other 
hand, insertion of a transjugular 
intrahepatic portosystemic 
stent-shunt (TIPSS), which is a 
well-established treatment for 
portal hypertension, is shown by 
Berres et al. to be associated 
with an increase in CXCL9, a 
C-X-C motif chemokine. High 
hepatic and portal venous 
concentrations of CXL9 were 
strong predictors of mortality 
indicating that TIPSS insertion 
may induce inflammation in 
some patients.
THE KIDNEY IN 
CIRRHOSIS
Terlipressin makes 
kidney sick? Issues 
with CLKD
Solà Verges et al. describe an 
intriguing early observation 
of transient proteinuria 
in patients treated with 
terlipressin; the mechanism 
and implication of this remains 
uncertain. 
Nilles et al. provide novel data 
that challenges the long held 
view that combined liver-kidney 
transplantation protects the 
kidneys from rejection. Their 
data rejects this long held 
view providing evidence 
that about 20% patients 
experience renal rejection.
LIVER 
TRANSPLANTATION
Living donors maintain 
good quality of life
Ladner et al. show in an exciting 
new study that health related 
quality of life of the majority of 
living donors are maintained 
even 11 years after they have 
donated their livers providing 
strong support that living donor 
liver transplantation is a valuable 
organ source.
ACUTE LIVER FAILURE
Unexpected molecules 
in virus-induced ALF
Guo et al. elegantly demonstrate 
the critical role of C5a 
anaphylatoxin chemotactic 
receptor 1 (a member of the 
G-protein coupled receptor 1 
family, also known as C5aR or 
CD88), tumor necrosis factor (a 
multifunctional pro-inflammatory 
cytokine also known as 
cachectin or TNF-α) and 
filaggrin-2 (a member of S100-
fused protein family also known 
as FGL-2) in an intertwined 
network that contributes 
to pathogenesis of virus-
induced acute liver failure 
pointing to potentially novel 
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